Single dose OKT3: adverse effects, pharmacokinetics, and anti-OKT3 antibody response.
Madden
R L
RL
Dept. of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, OH 45267-0714.
Schroeder
T J
TJ
Alexander
J W
JW
First
M R
MR
D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D003967:Diarrhea / Q000209:etiology; D016903:Drug Monitoring; D005334:Fever / Q000209:etiology; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D016030:Kidney Transplantation; D018655:Lymphocyte Count; D016853:Muromonab-CD3 / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000276:immunology / Q000493:pharmacokinetics; D009325:Nausea / Q000209:etiology; D011292:Premedication; D016176:T-Lymphocyte Subsets / Q000473:pathology; D014019:Tissue Donors; D014839:Vomiting / Q000209:etiology
D000888:Antibodies, Anti-Idiotypic; D016853:Muromonab-CD3